Jasper Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Jasper Therapeutics, Inc. has filed its 2023 Form 10-K, detailing its financial performance and operations.</b>

AI Summary

Jasper Therapeutics, Inc. (JSPRW) filed a Annual Report (10-K) with the SEC on March 5, 2024. Jasper Therapeutics, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and has its principal executive offices in Redwood City, California. Jasper Therapeutics' common stock trades on The Nasdaq Stock Market LLC under the symbol JSPR. Redeemable warrants, exercisable for shares of common stock at $115.00, also trade on The Nasdaq Stock Market LLC under the symbol JSPRW. The company has submitted all required reports for the preceding 12 months and has been subject to filing requirements for the past 90 days.

Why It Matters

For investors and stakeholders tracking Jasper Therapeutics, Inc., this filing contains several important signals. This filing provides a comprehensive overview of Jasper Therapeutics' financial health and strategic direction for the fiscal year 2023, crucial for investors assessing the company's current standing and future prospects. The inclusion of details on its common stock (JSPR) and warrants (JSPRW) trading on Nasdaq is important for market participants tracking the company's securities.

Risk Assessment

Risk Level: low — Jasper Therapeutics, Inc. shows low risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate red flags, indicating a routine disclosure of financial and operational information.

Analyst Insight

Investors should review the full 10-K filing for detailed financial statements, risk factors, and management's discussion and analysis to form an informed investment decision.

Key Numbers

• 2023-12-31 — Fiscal Year End (The report covers the fiscal year ended on this date.)
• 001-39138 — Commission File Number (SEC file number for Jasper Therapeutics, Inc.)
• 84-2984849 — IRS Number (Employer Identification Number.)
• 2024-03-05 — Filing Date (Date the 10-K was filed.)
• $115.00 — Warrant Exercise Price (Price at which redeemable warrants can be exercised.)

Key Players & Entities

• Jasper Therapeutics, Inc. (company) — Filer of the 10-K report.
• 2023 (date) — Fiscal year ended December 31, 2023.
• Delaware (jurisdiction) — State of incorporation.
• Redwood City, CA (location) — Principal executive offices.
• JSPR (ticker) — Trading symbol for common stock.
• JSPRW (ticker) — Trading symbol for redeemable warrants.
• The Nasdaq Stock Market LLC (company) — Exchange where securities are registered.
• $115.00 (dollar_amount) — Exercise price for redeemable warrants.

FAQ

Industry Context

Jasper Therapeutics operates in the biotechnology sector, focusing on developing therapeutics. This 10-K provides insights into their progress and financial standing within this industry.

Regulatory Implications

The filing adheres to SEC regulations for annual reports (Form 10-K) under the Securities Exchange Act of 1934, ensuring compliance with disclosure requirements.

What Investors Should Do

1. Review the full Form 10-K for detailed financial statements and operational updates.
2. Analyze the risk factors section for potential challenges and uncertainties.
3. Monitor future filings and news releases for developments related to Jasper Therapeutics' pipeline and strategy.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
• 2024-03-05: Filing Date — Date the Form 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial 10-K filing for the fiscal year 2023, following the company's operational period.

Key Financial Figures

• $0.0001 — istered Voting Common Stock, par value $0.0001 per share JSPR The Nasdaq Stock Market
• $115.00 — ng Common Stock at an exercise price of $115.00 JSPRW The Nasdaq Stock Market LLC S
• $13.70 — rant's common stock on June 30, 2023 of $13.70 (after giving effect to the 1-for-10 re

Filing Documents

• f10k2023_jaspertherap.htm (10-K) — 1640KB
• f10k2023ex4-3_jasper.htm (EX-4.3) — 52KB
• f10k2023ex10-35_jasper.htm (EX-10.35) — 19KB
• f10k2023ex10-36_jasper.htm (EX-10.36) — 19KB
• f10k2023ex23-1_jasper.htm (EX-23.1) — 2KB
• f10k2023ex31-1_jasper.htm (EX-31.1) — 10KB
• f10k2023ex31-2_jasper.htm (EX-31.2) — 10KB
• f10k2023ex32-1_jasper.htm (EX-32.1) — 7KB
• f10k2023ex97_jasper.htm (EX-97) — 42KB
• image_001.jpg (GRAPHIC) — 20KB
• image_002.jpg (GRAPHIC) — 28KB
• image_003.jpg (GRAPHIC) — 30KB
• image_004.jpg (GRAPHIC) — 14KB
• image_005.jpg (GRAPHIC) — 15KB
• image_006.jpg (GRAPHIC) — 607KB
• ex10-35_001.jpg (GRAPHIC) — 20KB
• ex10-36_001.jpg (GRAPHIC) — 20KB
• 0001213900-24-020114.txt (&nbsp;) — 8656KB
• jspr-20231231.xsd (EX-101.SCH) — 67KB
• jspr-20231231_cal.xml (EX-101.CAL) — 40KB
• jspr-20231231_def.xml (EX-101.DEF) — 305KB
• jspr-20231231_lab.xml (EX-101.LAB) — 551KB
• jspr-20231231_pre.xml (EX-101.PRE) — 306KB
• f10k2023_jaspertherap_htm.xml (XML) — 649KB

of this Annual Report on Form 10-K

Part III of this Annual Report on Form 10-K. TABLE OF CONTENTS PART I Item 1.

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 24 Item 1B. Unresolved Staff Comments 81 Item 1C. Cybersecurity 81 Item 2.

Properties

Properties 81 Item 3.

Legal Proceedings

Legal Proceedings 81 Item 4. Mine Safety Disclosures 81 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 82 Item 6. [Reserved] 82 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 83 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 95 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data F-1 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 96 Item 9A.

Controls and Procedures

Controls and Procedures 96 Item 9B. Other Information 96 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 96 PART III Item 10. Directors, Executive Officers and Corporate Governance 97 Item 11.

Executive Compensation

Executive Compensation 97 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 97 Item 13. Certain Relationships and Related Transactions, and Director Independence 97 PART IV Item 14. Principal Accountant Fees and Services 98 Item 15. Exhibit and Financial Statement Schedules 98 Item 16. Form 10–K Summary 102 i JASPER THERAPEUTICS, INC. As used in this Annual Report on Form 10-K, unless the context requires otherwise, references to the "Company", "Jasper", "we", "us", "our", and similar terms refer to Jasper Therapeutics, Inc., a Delaware corporation formerly known as Amplitude Healthcare Acquisition Corporation ("AMHC"), and its consolidated subsidiary. References to "Old Jasper" refer to the private Delaware corporation that is now our wholly-owned subsidiary and named Jasper Tx Corp. (formerly known as Jasper Therapeutics, Inc.). On September 24, 2021, we consummated the previously announced Business Combination (pursuant to the Business Combination Agreement, dated May 5, 2021, by and among AMHC, Ample Merger Sub, Inc. ("Merger Sub") and Old Jasper). Pursuant to the terms of the Business Combination Agreement, a business combination (herein referred to as the "Business Combination" or "Reverse Recapitalization" for accounting purposes) between AMHC and Old Jasper was effected through the merger of Merger Sub with and into Old Jasper with Old Jasper surviving as AMHC's wholly-owned subsidiary. In connection with the Business Combination, AMHC changed its name from Amplitude Healthcare Acquisition Corporation to Jasper Therapeutics, Inc. Unless otherwise noted or the context requires otherwise, references to our "common stock" refer to our voting common stock, par value $0.0001 per share. In addition, except as otherwise indicated, all information in this Annual Report on Form 10-K gives effect to the 1-for-10 reverse stock split of the common stock that was effected on January 4, 2024. CAUTIONARY NOTE REGARDING FORWAR

View Full Filing

View this 10-K filing on SEC EDGAR